Evidence map›Paper›PMID 31032988›Full record

ArticleBiomedical chromatography : BMC2019

Enantioseparation of 5-chloro-2-{2-[3,4-dihydroisoquinoline-2(1H)-yl]ethyl}-2-methyl-2,3-dihydro-1H-inden-1-one (SYA 40247), a high-affinity 5-HT

Edem K Onyameh, Barbara A Bricker, Edward Ofori, Seth Y Ablordeppey

Open access · greenAbstract read
In one paragraph

Article in Biomedical chromatography : BMC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Design and discovery of a high affinity, selective and β-arrestin biased 5-HTMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022
    Article
  2. New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.European journal of medicinal chemistry · 2021
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Edem K OnyamehDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL, USA.
Barbara A BrickerDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL, USA.
Edward OforiDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL, USA.
Seth Y AblordeppeyDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL, USA.ORCID https://orcid.org/0000-0003-0174-1153
Florida Agricultural and Mechanical University · US

Funding

A New Approach for the Development of Novel Antipsychotic DrugsSC1GM116724 · NIGMS · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI ABLORDEPPEY, SETH Y · 2016 to 2019
$1.4M
AnxiolytechNational Institute of General Medical Sciences 5SC1GM116724-03NIGMS NIH HHS SC1 GM116724
6 · The paper itself

Abstract

In previous structure-activity relationship studies to identify new and selective 5-HT

Indexed as

AmyloseChromatography, High Pressure LiquidIndenesIsoquinolinesLigandsPhenylcarbamatesReceptors, SerotoninStereoisomerismAmyloseChiralpak ADIndenesIsoquinolinesLigandsPhenylcarbamatesReceptors, Serotoninserotonin 7 receptor5-HT7 ligandenantioseparationHPLCpolarimetersemi-preparative scale

Identifiers

PMID31032988
PMCPMC6685742
OpenAlexW2942988328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.